
Roche licences antiviral nucleoside from Atea
Under the agreement, Roche will pay US$350m in cash for ex US-distribution of Atea Pharmaceuticals antiviral Phase II candidate. Atea has the option...

Priothera closes €30m Series A financing
The Irish cancer specialist Priothera Limited said it will use the the proceed sto advance its S1P receptor modulator mocravimod to Ohase...

Cell and gene therapy specialist Minaris expanding
In Europe, the Showa Denko Materials Co., Ltd. subsidiary will invest US$40.7 million to build a new state-of-the-art facility in proximity to an...

Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
Cancer antibody specialist BioInvent International AB has granted the exclusive rights to market its anti-FcγRIIB antibody, BI-1206, in China,...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

EU approves second COVID-19 vaccine
The EU has secured a total of 160 million doses of mRNA-1273 from the US-American manufacturer Moderna, which has outsourced production sites on the...

Biotech companies launch Biotech Austria
According to Apeiron CEO and Biotech Austria founding president Peter LLewellyn-Davies, Austria's vibrant biotech sector needs a voice that can be...